Indirect Treatment Comparison of Adjunctive Treatments for Patients with Parkinson’s Disease Experiencing Motor Complications
Objective: Evaluate the comparative efficacy of treatment options for Parkinson's disease (PD) motor complications using indirect treatment comparison. Background: Amantadine delayed release/extended release (DR/ER) capsules…Analysis of Amantadine formulations for OFF and Dyskinesia in Parkinson Disease
Objective: Evaluate the effects of amantadine formulations on the treatment of OFF and dyskinesia in Parkinson’s patients. Background: There are currently three formulations of amantadine…Amantadine-induced negative myoclonus in a patient with Parkinson’s disease: A case report
Objective: To report a case of amantadine-induced negative myoclonus in a patient with Parkinson’s disease. Background: Parkinson’s disease is a progressive neurodegenerative disease that involves…Correlations between amantadine usage, gait, and cognition in PSP: a post hoc analysis of the davunetide trial
Objective: Amantadine anecdotally improves gait and balance in PSP, potentially by increasing alertness, but there are no definitive data to support this observation. We investigated…Parkinsonism, delayed chorea and dystonia caused by extrapontine myelinolysis
Objective: To describe two case reports of patients with movement disorders due to extrapontine myelinolysis. Background: Central Pontine Myelinolysis (CPM) and Extra pontine myelinolysis (EPM)…Gocovri Dose Adjustment in Elderly Parkinson’s Patients at Risk for Renal Impairment: Implications from an Exposure Simulation Model
Objective: Evaluate amantadine exposure following Gocovri® (amantadine) extended release capsules dosing regimens in renal impairment, using pharmacokinetic (PK) modeling and simulations. Background: Gocovri bedtime dosing…The Efficacy and Safety of Gocovri Based on Age: Special Population Analyses of a Phase 3 Study Program
Objective: To assess patient outcomes and adverse events in Parkinson’s disease (PD) patients treated with Gocovri® (amantadine) extended release capsules at bedtime for dyskinesia, by…Utilization patterns of Amantadine in Parkinson’s Disease patients enrolled in the French COPARK study
Objective: To explore amantadine IR utilization patterns in the French COPARK study. Background: Immediate release (IR) amantadine is marketed for the treatment of early and…Safety of Gocovri in Clinical Practice: One-year Post-launch Pharmacovigilance Data
Objective: To assess the real-world safety profile of Gocovri® (amantadine) extended release capsules one year post-launch. Background: Gocovri received FDA approval in August 2017 for…High dose amantadine therapy may cause increased falling in Parkinson’s patients
Objective: To report a possible association between high dose amantadine and increased falling in patients with Parkinson’s disease (PD). Background: Amantadine is used in PD…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.